ClinicalTrials.gg
CompletedNCT02233023Updated Sep 8, 2014

Ophthalmologic Safety of Long Term Treatment With Pramipexole Compared to Bromocriptine or Other Dopamine Agonists in Patients With Parkinson's Disease

A Phase 4 interventional study of Pramipexole and Bromocriptine and other dopamine agonists in Parkinson Disease, sponsored by Boehringer Ingelheim. Completed. Per ClinicalTrials.gov, last updated 2014-09-08.

Sponsored by Boehringer Ingelheim · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
705
Allocation
Non-randomized
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 26 studies testing pramipexole in Parkinson Disease — none open to participants now, none under way, none of them phase 3. Pramipexole · Parkinson Disease.

Enrollment
Largest of 26
705 · median 224
Started
1998
with 1 other
Phase 4
10 of 26
none open now
Registered
22nd of 26
by date
Lead sponsor
16 of 26
Boehringer Ingelheim

Among the 26 studies testing pramipexole in Parkinson Disease, this one has the largest enrollment, is one of 2 that started in 1998, is one of 10 in phase 4, and was the 22nd registered.

Parkinson Disease

4,578 studies on the registry are indexed under Parkinson Disease; 1,085 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

None of the 26 studies testing pramipexole in Parkinson Disease is open now. The open studies under Parkinson Disease, anywhere →

About pramipexole

Pramipexole: first FDA approval 1997 (MIRAPEX), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 748 Parkinson Disease studies recruiting now, 311 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 26 studies testing pramipexole in Parkinson Disease as a file.
02

Study summary

Study to assess and compare the safety of long term oral treatment for Parkinson's Disease with pramipexole versus bromocriptine or other dopamine agonists, by measuring cross-sectional the incidence of ophthalmologic disturbances, especially signs of retinal degeneration, in a matched pair design

03

Conditions studied

  • Parkinson Disease

Browse trials for

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with idiopathic Parkinson's Disease
  • Patients treated consecutively with either pramipexole or bromocriptine (or other dopamine agonists except ropinirole) for at least two and a half years (i.e. 30 months). Interruptions of ongoing dopamine agonists treatment for less than one month per year duration are acceptable, however, interruptions within the last 6 months are not acceptable. Patients currently participating in ongoing open-label extension trials with pramipexole may be included if they meet the requirement of 30 month treatment
  • Written in accordance with Good Clinical Practice (GCP) and local legislation

Exclusion criteria

Exclusion Criteria:

  • Patients who have been treated less than two and a half years (i.e. 30 months) with their actual dopamine agonist (regardless of the duration of treatment with a previous dopamine agonist)
  • Patient treated with ropinirole
  • Patients with any of the following:

    • Patients with a hereditary retinal disease and/or a family history of hereditary retinal disease
    • Patients with a history of drug-induced retinopathies
    • Patients with a history of surgically or laser-treated diabetic retinopathy
  • Patients with atypical parkinsonian syndromes due to drugs, metabolic disorders, encephalitis or degenerative diseases (e.g. progressive, supranuclear palsy, multisystem atrophy)
  • Dementia or other disorders that could impair the signing of
  • Patients who are participating in other drug studies or who receive other drugs within 30 days prior to the first visit (patients currently participating in ongoing open-label extension trials with pramipexole may be included if they meet the requirement of 30 months treatment duration
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
705 participants (actual)

Study arms

  • Experimental
    Pramixpexole

    Drug: Pramipexole

  • Active comparator
    Bromocriptine and other dopamine agonists

    Drug: Bromocriptine and other dopamine agonists

Interventions

  • DrugBromocriptine and other dopamine agonists
06

What researchers measure

Primary outcomes

  1. Incidence of drug related signs of retinal degeneration

    based on the evaluation of assessors blind to the treatment allocation

    Time frame: up to 8 months

Secondary outcomes

  1. Assessment of ophthalmological history

    Time frame: within 2 month after neurologic visit

  2. Assessment of visual acuity

    Time frame: within 2 month after neurologic visit

  3. Number of abnormal findings in clinical examination in miosis and mydriasis

    including ophthalmoscopy

    Time frame: within 2 month after neurologic visit

  4. Assessment of intraocular pressure (mmHg)

    Time frame: within 2 month after neurologic visit

  5. Assessment of colour vision

    using the Hardy-Rand-Rittler (H-R-R) pseudoisochromatic plates

    Time frame: within 2 month after neurologic visit

  6. Findings in kinetic perimetry

    Time frame: within 2 month after neurologic visit

  7. Percentage of patients with elevated dark adaptation thresholds

    Time frame: within 2 month after neurologic visit

  8. Assessment of Parkinson's Disease stage rated by modified Hoehn and Yahr Scale

    Time frame: within less than 2 months before ophthalmologic visit

  9. Assessment of Parkinson's Disease stage rated of unified Parkinson's Disease Rating Scale (UPDRS) Part IV

    Time frame: within less than 2 months before ophthalmologic visit

  10. Number of patients with adverse events

    Time frame: up to 2 month after neurologic visit

  11. Findings in standardised electroretinography (ERG)

    performed according to International Standardization Committee for the Electrophysiology of Vision (ISCEV) standard

    Time frame: within 2 monhts after neurologic visit

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 1998 and a primary completion of Jun 2000. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 4, 2014
First posted
Sep 8, 2014
Start
Jun 1998
Primary completionActual
Jun 2000
Last update
Sep 8, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 8, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02233023
Responsible party
Sponsor
First posted
Sep 8, 2014
Start date
Jun 1998
Primary completion
Jun 2000
Last update
Sep 8, 2014
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pramipexole

Start the discussion